Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 3/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.31 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1170455 | 1.00 | HTR1A (0.45) | HTR1AMEN1KMT2ATSHRMAPK1 | |
| SCHEMBL12595155 | 0.82 | L3MBTL1 (0.35) | HTR1AHTR7MAPTALDH1A1LMNA | |
| SCHEMBL12865229 | 0.82 | PTPN1 (0.33) | HTR1ATSHRHTR7MAPTALDH1A1 | |
| SCHEMBL12595162 | 0.82 | HPGD (0.34) | HTR1AHTR7MAPTALDH1A1LMNA | |
| SCHEMBL12595154 | 0.82 | L3MBTL1 (0.35) | HTR1AHTR7MAPTALDH1A1LMNA | |
| SCHEMBL7890511 | 0.79 | HRH3 (0.39) | MEN1KMT2AMAPK1MAPTALDH1A1 | |
| SCHEMBL18092254 | 0.78 | PTPN1 (0.35) | ALDH1A1 | |
| SCHEMBL1170456 | 0.76 | HTR1A (0.40) | HTR1AMEN1KMT2ATSHRMAPK1 | |
| SCHEMBL1169962 | 0.76 | HTR1A (0.40) | HTR1AMEN1KMT2ATSHRMAPK1 | |
| SCHEMBL11356421 | 0.76 | HRH3 (0.32) | MEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1594440-B1 | THE SELECTIVE AND SPECIFIC PREPARATION OF DISCRETE PEG COMPOUNDS | QUANTA BIODESIGN LTD (US) | 2019-07-03 | — | — | EP | disclosed |
| US-8637711-B2 | Selective and specific preparation of discrete PEG compounds | QUANTA BIODESIGN, LTD. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637711-B2 | Selective and specific preparation of discrete PEG compounds | QUANTA BIODESIGN, LTD. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637711-B2 | Selective and specific preparation of discrete PEG compounds | QUANTA BIODESIGN, LTD. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20110124844-A1 | Selective and Specific Preparation of Discrete Peg Compounds | AUDAX PRIVATE DEBT LLC, AS AGENT | 2011-05-26 | — | — | US | disclosed |
| US-20110124844-A1 | Selective and Specific Preparation of Discrete Peg Compounds | AUDAX PRIVATE DEBT LLC, AS AGENT | 2011-05-26 | — | — | US | disclosed |
| US-20110124844-A1 | Selective and Specific Preparation of Discrete Peg Compounds | AUDAX PRIVATE DEBT LLC, AS AGENT | 2011-05-26 | — | — | US | disclosed |
| US-7888536-B2 | Selective and specific preparation of discrete PEG compounds | QUANTA BIODESIGN, LTD. (US) | 2011-02-15 | — | — | US | disclosed |
| US-7888536-B2 | Selective and specific preparation of discrete PEG compounds | QUANTA BIODESIGN, LTD. (US) | 2011-02-15 | — | — | US | disclosed |
| US-7888536-B2 | Selective and specific preparation of discrete PEG compounds | QUANTA BIODESIGN, LTD. (US) | 2011-02-15 | — | — | US | disclosed |
| EP-1594440-A4 | THE SELECTIVE AND SPECIFIC PREPARATION OF DISCRETE PEG COMPOUNDS | QUANTA BIODESIGN LTD (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20060020134-A1 | Selective and specific preparation of discrete peg compounds | AUDAX PRIVATE DEBT LLC, AS AGENT | 2006-01-26 | — | — | US | disclosed |
| EP-1594440-A2 | THE SELECTIVE AND SPECIFIC PREPARATION OF DISCRETE PEG COMPOUNDS | Quanta Biodesign, Ltd. (US) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004073620-A2 | THE SELECTIVE AND SPECIFIC PREPARATION OF DISCRETE PEG COMPOUNDS | QUANTA BIODESIGN, LTD (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124844-A1 | Selective and Specific Preparation of Discrete Peg Compounds | PARG, GNE, PAM | HTR1A 4681/4885MEN1 2562/4885KMT2A 4631/4885 |
| US-20060020134-A1 | Selective and specific preparation of discrete peg compounds | PARG, GNE, PAM | HTR1A 4681/4885MEN1 2562/4885KMT2A 4631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.